Cargando…
SYN-004 (ribaxamase) prevents New Onset Clostridium difficile Infection by Protecting the Integrity Gut Microbiome in a Phase 2b Study
BACKGROUND: Clostridium difficile infections (CDI) are an “urgent threat,” but there are no approved drugs or vaccines to prevent new onset CDI. SYN-004 (ribaxamase) is a β-lactamase designed to be orally administered with IV β-lactam antibiotics and remain localized in the intestine to degrade anti...
Autores principales: | Kokai-Kun, John, Roberts, Tracey, Coughlin, Olivia, Whalen, Heidi, Le, Charles, Da Costa, Christopher, Sliman, Joseph |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631845/ http://dx.doi.org/10.1093/ofid/ofx162.029 |
Ejemplares similares
-
The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies
por: Kokai-Kun, John F., et al.
Publicado: (2017) -
1337. SYN-004 (Ribaxamase) Protects the Gut Microbiome of Patients Treated With Ceftriaxone From Disruption and Reduces the Emergence of Antimicrobial Resistance
por: Kokai-Kun, John, et al.
Publicado: (2018) -
Ribaxamase, an Orally Administered β-Lactamase, Diminishes Changes to Acquired Antimicrobial Resistance of the Gut Resistome in Patients Treated with Ceftriaxone
por: Kokai-Kun, John F, et al.
Publicado: (2020) -
Developing Gut Microbiota Exerts Colonisation Resistance to Clostridium (syn. Clostridioides) difficile in Piglets
por: Grześkowiak, Łukasz, et al.
Publicado: (2019) -
71 Alterations in the Gut Microbiome in Recurrent Clostridium difficile Infection
por: Wang, Gary, et al.
Publicado: (2014)